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c-Abl is a non-receptor tyrosine kinase whose activ-
ity is tightly controlled in vivo through unknown
mechanisms. Recent studies suggest that c-Abl may
be regulated in different cellular contexts by distinct
lipids.
c-Abl is a clinically important tyrosine kinase whose
activity is dysregulated by the t(9;22) Philadelphia chro-
mosome translocation in chronic myeloid leukemia
(CML), a translocation that results in the fusion of the
BCR gene to the ABL gene. The critical role of Bcr-Abl
in CML was demonstrated by reproduction of the
disease in mice upon expression of Bcr–Abl in bone
marrow stem cells and by the therapeutic efficacy of
imatinib, a small molecule inhibitor of the Abl kinase, in
CML patients. Obviously, the tyrosine kinase activity of
c-Abl needs to be precisely controlled within the cell.
However, the mechanism of regulation of c-Abl cat-
alytic activity has remained elusive [1].
The ubiquitously expressed 140 kDa c-Abl protein
localizes to the cell nucleus, plasma membrane, and
actin cytoskeleton [2]. There are two different c-Abl iso-
forms (types Ia and Ib) that result from the expression
of two small alternative first exons. Type Ib c-Abl con-
tains a C14 myristoyl fatty acid moiety covalently linked
to the amino terminus and is expressed at higher levels
than type Ia, which is not myristoylated. The amino-ter-
minal half of Abl resembles Src family kinases and con-
tains Src homology 3 (SH3), SH2 and catalytic domains,
but Abl differs from Src by possessing a large (60 kDa)
carboxy-terminal domain. c-Abl has been implicated in
signaling pathways initiated by growth factors, ionizing
radiation, oxidative stress, and integrin stimulation, and
in signaling during neuronal development [2] but the
mechanisms of activation of Abl by these diverse
stimuli have been obscure. Recent studies now suggest
that membrane-associated c-Abl may be negatively
regulated by phosphatidylinositol lipids [3], while in
other contexts Abl may be autoinhibited through
intramolecular association of the amino-terminal myris-
toyl group with the catalytic domain [4,5].
Negative Regulation of c-Abl by PtdIns(4,5)P2
A previous study [6] demonstrated that the kinase activ-
ity of the membrane-associated c-Abl pool was tran-
siently increased upon treatment of fibroblasts with
certain growth factors, including platelet-derived growth
factor (PDGF), and that Abl was required for PDGF-
induced membrane ruffling. Activation of Abl by PDGF
was greatly impaired in fibroblasts deficient in c-Src,
Yes, and Fyn or in wild-type fibroblasts expressing a
chimeric PDGF receptor lacking the Src-binding sites at
tyrosines 579 and 581. Since the catalytic activity of
purified c-Abl is stimulated by tyrosine phosphorylation
[7], these observations suggested that Src kinases are
directly activated by the PDGF receptor, and then phos-
phorylate and activate c-Abl in a secondary reaction. In
a follow-up study in Nature Cell Biology, Ann Marie Pen-
dergast and co-workers [3] have now shown that PDGF
receptor signaling also overcomes negative regulation
of c-Abl mediated by membrane phospholipids.
The key observation was that the binding site for
phospholipase C-γ1 (PLC-γ1) at Tyr1021 on the PDGF
receptor is required in addition to the Src-binding sites
for robust PDGF-induced activation of c-Abl (Figure 1).
Activation of c-Abl by PDGF is impaired by pre-treat-
ment of cells with a PLC-γ inhibitor, diminished in
fibroblasts lacking PLC-γ1, and restored by expression
of wild-type but not phospholipase-inactive PLC-γ1.
This finding suggests that either the substrate of PLC-γ, 
phosphatdylinositol-4,5-bisphosphate (PtdIns(4,5)P2),
inhibits Abl or the products of the reaction, inositol-
3,4,5-triphosphate (InsP3) and diacylglycerol, stimulate
Abl. Pendergast and colleagues [3] found that InsP3
does not affect Abl kinase activity in vitro, but addition
of liposomes containing PtdIns(4,5)P2 inhibits c-Abl and
this is significantly enhanced by pharmacological levels
of calcium (400–800 µM). Conversely, depletion of cel-
lular PtdIns(4,5)P2 by ectopic expression of a yeast
inositol phosphatase (Inp54) results in marked activa-
tion of endogenous c-Abl even in the absence of PDGF
stimulation. Adding a final regulatory twist to the story,
the Pendergast group went on to demonstrate recipro-
cal SH2-dependent complex formation between acti-
vated c-Abl and PLC-γ1, leading to phosphorylation of
PLC-γ1 predominantly at tyrosines 771 and 1003 and
inhibition of PLC-γ1 phospholipase activity. This regu-
lation probably represents a negative feedback loop
that serves to limit the activation of PLC-γ1 and c-Abl
following growth factor stimulation (Figure 1).
A Structural Role for the Amino-Terminal Myristoyl
Moiety in Autoinhibition of Type Ib c-Abl
Src kinases are maintained in the inactive state through
intramolecular binding of the SH2 domain to a phos-
phorylated tyrosine (Tyr527 in c-Src) in the carboxy-ter-
minal tail. In this structure, the SH3 domain makes an
atypical interaction with a single proline (Pro250) in the
linker region between the SH2 and catalytic domains
(SH2-CD linker), forcing the catalytic domain into a
closed conformation [8]. c-Abl is dysregulated by muta-
tions in the SH3 domain that interfere with ligand
binding [9], and a seminal 1998 paper from the labora-
tory of Giulio Superti-Furga demonstrated that mutation
of the homologue of Pro250 in c-Abl also activates Abl
[10], suggesting that Abl shares this part of the regula-
tory mechanism with Src. Point mutations in the con-
nector region between SH3 and SH2 also dysregulate
both Src and Abl [11,12], implying that dynamic cou-
pling between the two domains is necessary for proper
regulation of both kinases. However, Abl has no
detectable tyrosine phosphorylation when expressed at
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physiological levels [9] and is not dysregulated by dele-
tion of the entire carboxyl terminus or by point muta-
tions in the SH2 domain that block phosphotyrosine
binding [13]. Thus, it has been an enigma how an inhib-
ited state of Abl could be maintained when Abl lacks
the SH2–Tyr527 interaction that is essential for regula-
tion of Src.
In a pair of recent papers in Cell, the laboratories of
Superti-Furga and John Kuriyan have collaborated to
give us the first structural glimpse of Abl in the inac-
tive state. An amino-terminal fragment of Abl that
lacks the first exon and ends with the catalytic domain
would crystallize only when myristate fatty acid was
added in trans [5]. The resulting structure reveals the
myristate group bound in a deep hydrophobic pocket
within the carboxy-terminal lobe (C-lobe) of the cat-
alytic domain, inducing a kink in a carboxy-terminal
αI-helix that permits close docking of the SH2 domain
to the back face of the C-lobe via a series of hydrogen
bonds. The overall structure bears a striking similarity
to inactive Src, with the SH3 domain engaged with the
Pro250 homologue in the SH2-CD linker. The accom-
panying paper [4] provides biochemical and genetic
support for the structure by demonstrating that Abl
sequences amino-terminal to the SH3 domain (the
amino-terminal ‘cap’) and the myristoyl group are
required for proper regulation of type Ib Abl kinase
activity upon overexpression in vivo. The catalytic
activity of Abl is also increased by mutations at the
predicted SH2–kinase domain interface and by phos-
photyrosine ligands that may disrupt this interaction.
Multilevel Regulation of c-Abl
These recent studies add to an emerging picture of 
c-Abl as a multifunctional protein localized to at 
least three different cellular compartments and whose 
catalytic activity is regulated on several levels by dif-
ferent mechanisms (Figure 2). In the membrane-asso-
ciated pool of Abl, the myristoyl group is presumably
inserted in the lipid bilayer and unavailable for binding
to the C-lobe. In this context, inhibition of Abl may be
mediated by PtdIns(4,5)P2, possibly acting through an
accessory protein. One could speculate that
PtdIns(4,5)P2, which binds directly to the catalytic
domain of Abl [3], might cause a conformational
change in the C-lobe similar to that induced by myris-
tate. In contrast, the cytoplasmic and cytoskeletal
pools of Abl may assume an autoinhibited state sug-
gested by the crystal structure [5], with the myristoyl
group buried in the C-lobe. This inactive conformation
could be disrupted by several routes, including auto-
or transphosphorylation at regulatory tyrosines in the
activation loop of the catalytic domain and the SH2-
CD linker [7], or displacement of the SH2 or SH3
domains, or the myristoyl group [4].
However, there are several aspects of Abl biology
that must still be explained. c-Abl gains significant
catalytic activity when overexpressed [14] or upon
purification [7] and its enzymatic activity in solution is
unaffected by loss of the myristoyl group [15]. Fur-
thermore, when expressed at physiological levels,
type Ia c-Abl is regulated despite the lack of a myris-
toyl group, as is a c-Abl Ib mutant lacking the myris-
toylation site and first 45 residues of the cap [16].
These observations suggest that Abl may also be reg-
ulated in vivo by cellular factors. In the studies of
Kuriyan and colleagues [4], the entire amino terminus
of type Ib c-Abl (including the myristoyl group) crys-
tallized poorly and the amino-terminal cap was disor-
dered in both structures, hinting that an additional
protein(s) might act in trans to stabilize this conforma-
tion. Candidate Abl inhibitory proteins include the
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Figure 1. Regulation of c-Abl by PDGF.
(A) Unstimulated cells depicting PDGFβ receptor in purple with split kinase domain and tyrosine autophosphorylation sites (Y); PLC-γ1
in orange with two pleckstrin homology domains (PH), tandem amino- and carboxy-terminal SH2 domains and SH3 domain, and split
catalytic domain (Lipase); and type Ib c-Abl in blue with amino-terminal myristoyl group (Myr) engaged in the membrane, SH3 bound
intramolecularly to Pro242, and the ATP-binding and catalytic lobes of the kinase domain in closed conformation, bound to membrane
PI(4,5)P2 possibly via an accessory inhibitor protein (?, in green). (B) PDGF stimulation results in dimerization and autophosphorylation
of PDGFβ receptor, then recruitment and activation of Src kinases (yellow) and PLC-γ1. Src phosphorylates Abl at regulatory sites Y416
and perhaps Y245, while PLC-γ1 hydrolyzes PI(4,5)P2 to DAG and IP3, resulting in full activation of Abl. (C) Activated Abl and PLC-γ1
form a complex mediated in part by reciprocal SH2 binding (the specific SH2-phosphotyrosine interactions depicted here (?) are hypo-
thetical), resulting in phosphorylation of PLC-γ1 at Y771 and Y1003 and inhibition of lipase activity. Abl induces actin-rich membrane
ruffles through an unknown pathway (?) while the phospholipase reaction products DAG and IP3 activate PKC and calcium signaling.
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retinoblastoma protein for nuclear c-Abl [17] and the
peroxiredoxin Pag for cytoplasmic Abl [18]. We also
do not know what effect the Abl carboxyl terminus
may have on the inhibited form of Abl, as this entire
domain was missing from the crystal structure but
internal deletions in the carboxyl terminus can dys-
regulate Abl [19]. Lastly, there is a role for serine phos-
phorylation in regulation of Abl in some contexts, as
the ATM serine kinase phosphorylates and activates
nuclear c-Abl upon DNA damage [20]. Clearly, we
have more to learn about the intricacies of the regula-
tion of this fascinating kinase.
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Figure 2. Multilevel regulation of c-Abl.
Different cellular pools of Abl are depicted, with established and postulated (?) regulatory mechanisms shown by red lines. (A) Cyto-
plasmic c-Abl Ib shown in the autoinhibited state [5], with the myristoyl group (orange) buried in a pocket in the carboxy-terminal lobe
of the kinase domain, inducing a kink in the carboxy-terminal αI helix of this domain (orange rectangles) that permits close associa-
tion of the SH2 domain. (B) Type Ia c-Abl with a distinct amino-terminal sequence (green) that lacks myristate. The structure of this
isoform is unknown but is depicted with an extended αI helix and the SH2 domain disengaged. (C) Membrane-associated c-Abl Ib
with the myristoyl group inserted in the membrane, also depicted with an extended αI helix. The position of the SH2 domain in this
pool of Abl is not known. (D) Cytoskeletal c-Abl interacting with F-actin through a carboxy-terminal actin-binding domain [2]. An
inhibitory role for F-actin on Abl has also been proposed [1]. (E) Nuclear c-Abl, inhibited in G1 phase by Rb and activated through
ATM phosphorylation upon DNA damage.
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